Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies

Aims: Evofosfamide (TH-302) is a hypoxia-activated prodrug (HAP) that releases the DNA-damaging bromo-isophosphoramide mustard (Br-IPM) moiety selectively under hypoxic conditions. Since solid tumors are known to have hypoxic regions, HAPs in combination with chemotherapy or radiotherapy (XRT) will...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antioxid Redox Signal
Main Authors: Takakusagi, Yoichi, Kishimoto, Shun, Naz, Sarwat, Matsumoto, Shingo, Saito, Keita, Hart, Charles P., Mitchell, James B., Krishna, Murali C.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2018
Assuntos:
Original Research Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5725636/
https://ncbi.nlm.nih.gov/pubmed/28741367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/ars.2017.7106
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados